{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T03:57:54Z","timestamp":1786766274867,"version":"build-2736575974"},"reference-count":36,"publisher":"The Journal of Rheumatology","issue":"Suppl 2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2024,3,17]]},"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:p>In this debate at the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2023 annual meeting, arguments were made contrasting the first-line use of oral targeted small-molecule drugs vs biologic therapy for the treatment of moderate-to-severe psoriasis (PsO) after failure of conventional therapy. Arguments in favor of small-molecule drugs included good efficacy and safety, patient preference, cost savings, global health equity, and environmental stewardship. Arguments in favor of biologics included superior efficacy, excellent safety, availability of long-term data, pediatric regulatory approvals, and potential benefit for comorbidities. By the end of the debate, there was recognition of significant pros and cons of each approach. Both small-molecule drugs and biologic therapy are valuable options for PsO treatment, and their use can be tailored toward specific individuals or healthcare systems.<\/jats:p>","DOI":"10.3899\/jrheum.2024-0293","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T12:16:35Z","timestamp":1721045795000},"page":"89-92","source":"Crossref","is-referenced-by-count":4,"title":["GRAPPA Debate: Targeted Small Molecules Versus Biologics as First-Line Systemic Therapy After Conventional Therapy for Moderate-to-Severe Psoriasis"],"prefix":"10.3899","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7883-6439","authenticated-orcid":false,"given":"Wilson","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0064-8707","authenticated-orcid":false,"given":"April W.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5464-0439","authenticated-orcid":false,"given":"Kristina Callis","family":"Duffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2024,7,15]]},"reference":[{"key":"2024120403401081000_51.Suppl_2.89.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006"},{"key":"2024120403401081000_51.Suppl_2.89.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.07.002"},{"key":"2024120403401081000_51.Suppl_2.89.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.08.061"},{"key":"2024120403401081000_51.Suppl_2.89.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615975"},{"key":"2024120403401081000_51.Suppl_2.89.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022516"},{"key":"2024120403401081000_51.Suppl_2.89.6","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40257-023-00783-7","article-title":"Apremilast long-term safety up to 5 years from 15 pooled randomized, placebo-controlled studies of psoriasis, psoriatic arthritis, and Behcet\u2019s syndrome","volume":"24","author":"Mease","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"2024120403401081000_51.Suppl_2.89.7","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s13555-023-00892-5","article-title":"A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring","volume":"13","author":"Samuel","year":"2023","journal-title":"Dermatol Ther"},{"key":"2024120403401081000_51.Suppl_2.89.8","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/1346-8138.16746","article-title":"A discrete choice experiment on oral and injection treatment preferences among moderate-to-severe psoriasis patients in Japan","volume":"50","author":"Komine","year":"2023","journal-title":"J Dermatol"},{"key":"2024120403401081000_51.Suppl_2.89.9","doi-asserted-by":"crossref","first-page":"2177095","DOI":"10.1080\/09546634.2023.2177095","article-title":"Treatment patterns and healthcare costs among patients with psoriasis initiating apremilast or biologics: a retrospective claims database cohort analysis","volume":"34","author":"Wu","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"2024120403401081000_51.Suppl_2.89.10","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1080\/13696998.2019.1707209","article-title":"A cost-effective and budget impact analysis of apremilast in patients with psoriasis in the Italian setting","volume":"23","author":"Barbieri","year":"2020","journal-title":"J Med Econ"},{"key":"2024120403401081000_51.Suppl_2.89.11","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3390\/healthcare11020242","article-title":"Healthcare waste-a serious problem for global health","volume":"11","author":"Janik-Karpinska","year":"2023","journal-title":"Healthcare"},{"key":"2024120403401081000_51.Suppl_2.89.12","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/bjd.20568","article-title":"Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2","volume":"185","author":"Reich","year":"2021","journal-title":"Br J Dermatol"},{"key":"2024120403401081000_51.Suppl_2.89.13","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jaad.2020.11.022","article-title":"Long-term efficacy and safety of ixekizumab: a 5-year analysis of the UNCOVER-3 randomized controlled trial","volume":"85","author":"Blauvelt","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2024120403401081000_51.Suppl_2.89.14","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jaad.2023.07.1024","article-title":"Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up","volume":"89","author":"Papp","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2024120403401081000_51.Suppl_2.89.15","first-page":"CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"7","author":"Sbidian","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"2024120403401081000_51.Suppl_2.89.16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g4026"},{"key":"2024120403401081000_51.Suppl_2.89.17","first-page":"12","article-title":"The psoriasis treatment ladder: a clinical overview","volume":"8","author":"Loftholm","year":"2001","journal-title":"J Mod Pharm"},{"key":"2024120403401081000_51.Suppl_2.89.18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s13555-017-0198-x","article-title":"Long-term safety and effectiveness of adalimumab for moderate to severe psoriasis: results from 7-year interim analysis of the ESPRIT registry","volume":"7","author":"Menter","year":"2017","journal-title":"Dermatol Ther"},{"key":"2024120403401081000_51.Suppl_2.89.19","first-page":"1441","article-title":"Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies","volume":"13","author":"Gottlieb","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"2024120403401081000_51.Suppl_2.89.20","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s40264-021-01065-z","article-title":"Signal detection and methodological limitations in a real-world registry: learnings from the evaluation of long-term safety analyses in PSOLAR","volume":"44","author":"Bissonnette","year":"2021","journal-title":"Drug Saf"},{"key":"2024120403401081000_51.Suppl_2.89.21","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8128-x"},{"key":"2024120403401081000_51.Suppl_2.89.22","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70173-X"},{"key":"2024120403401081000_51.Suppl_2.89.23","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/jdv.16866","article-title":"Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis \u2013 time for a paradigm change","volume":"35","author":"Nogueira","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024120403401081000_51.Suppl_2.89.24","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.3346\/jkms.2022.37.e107","article-title":"The risk of tuberculosis in patients with inflammatory bowel disease treated with vedolizumab or ustekinumab in Korea","volume":"37","author":"Choi","year":"2022","journal-title":"J Korean Med Sci"},{"key":"2024120403401081000_51.Suppl_2.89.25","unstructured":"Griffiths C , Reich K , Gooderham M , Long term safety of ixekizumab in patients with moderate-to-severe plaque psoriasis up to 5 years: pooled data from 16 clinical trials. Poster P0372. Paper presented at: EADV Virtual Congress; 2020 October 29-31."},{"key":"2024120403401081000_51.Suppl_2.89.26","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12214"},{"key":"2024120403401081000_51.Suppl_2.89.27","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/1346-8138.16904","article-title":"Association between cardio-cerebrovascular disease and systemic antipsoriatic therapy in psoriasis patients using population-based data: a nested case-control study","volume":"50","author":"Kim","year":"2023","journal-title":"J Dermatol"},{"key":"2024120403401081000_51.Suppl_2.89.28","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.120.011199]"},{"key":"2024120403401081000_51.Suppl_2.89.29","unstructured":"Bristol Myers Squibb . New two-year deucravacitinib data reinforce durable efficacy and consistent safety profile in treatment of moderate to severe plaque psoriasis. [Internet. Accessed March 28, 2024.] Available from: https:\/\/news.bms.com\/news\/details\/2022\/New-Two-Year-Deucravacitinib-Data-Reinforce-Durable-Efficacy-and-Consistent-Safety-Profile-in-Treatment-of-Moderate-to-Severe-Plaque-Psoriasis\/default.aspx"},{"key":"2024120403401081000_51.Suppl_2.89.30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.19.2275"},{"key":"2024120403401081000_51.Suppl_2.89.31","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamadermatol.2020.0024","article-title":"Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"156","author":"Vaengebjerg","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2024120403401081000_51.Suppl_2.89.32","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211384"},{"key":"2024120403401081000_51.Suppl_2.89.33","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212196"},{"key":"2024120403401081000_51.Suppl_2.89.34","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1080\/09546634.2022.2059051","article-title":"Managing pediatric psoriasis: update on treatments and challenges-a review","volume":"33","author":"Hebert","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"2024120403401081000_51.Suppl_2.89.35","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/dom.14244","article-title":"Patients\u2019 preferences for once-daily oral versus once-weekly injectable diabetes medications: the REVISE study","volume":"23","author":"Boye","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2024120403401081000_51.Suppl_2.89.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.03.049"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2024-0293","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T11:41:17Z","timestamp":1733312477000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2024-0293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,15]]},"references-count":36,"journal-issue":{"issue":"Suppl 2","published-online":{"date-parts":[[2024,10,1]]},"published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.3899\/jrheum.2024-0293"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2024-0293","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,15]]}}}